Arcturus Therapeutics Holdings Inc (ARCT) is a Healthcare · Biotechnology company listed on NASDAQ. Price $16.03 (-5.32%), Market cap $0.20B, 52-week low–high $5.90 ~ $23.16.
Arcturus Therapeutics Holdings Inc., a messenger RNA medicines company, focuses on the development of liver and respiratory rare disease therapeutics. Its technology platforms include STARR, a self-amplifying mRNA technology platform, and LUNAR, a lipid-mediated delivery system. The company also develops ARCT-032 (LUNAR-CF), an mRNA therapeutic candidate for cystic fibrosis that is in Phase 2 clinical development; and ARCT-810 (LUNAR-OTC), which is in Phase 2 clinical development to address ornithine transcarbamylase (OTC) deficiency. In addition, it develops KOSTAIVE, a self-amplifying RNA vaccine for COVID-19; ARCT-2138 (LUNAR-FLU), which is in Phase1 clinical trial for the treatment of se
Financial statements, price targets, institutional (13F) holdings and related news for Arcturus Therapeutics Holdings Inc are updated in real time on BlackAll Trade.
Arcturus Therapeutics Holdings Inc trades at $16.03 (-5.32%). Real-time quotes and charts are available on BlackAll Trade.
Arcturus Therapeutics Holdings Inc has a market cap of about $0.20B.
Arcturus Therapeutics Holdings Inc., a messenger RNA medicines company, focuses on the development of liver and respiratory rare disease therapeutics. Its technology platforms include STARR, a self-am